Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBITDA Margin (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of EBITDA Margin data on record, last reported at 22.98% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 2694.0% year-over-year to 22.98%; the TTM value through Sep 2025 reached 30.48%, down 892.0%, while the annual FY2024 figure was 30.87%, 501.0% down from the prior year.
  • EBITDA Margin reached 22.98% in Q3 2025 per UTMD's latest filing, down from 48.99% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 51.17% in Q4 2022 and bottomed at 9.65% in Q4 2024.
  • Average EBITDA Margin over 5 years is 31.18%, with a median of 29.32% recorded in 2024.
  • The widest YoY moves for EBITDA Margin: up 2655bps in 2024, down -3596bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 32.1% in 2021, then surged by 59bps to 51.17% in 2022, then dropped by -11bps to 45.62% in 2023, then plummeted by -79bps to 9.65% in 2024, then skyrocketed by 138bps to 22.98% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 22.98% in Q3 2025, 48.99% in Q2 2025, and 38.71% in Q1 2025.